FROM YAHOO NEWS Latest news, live updates as 2024 election results loom HKSE - Delayed Quote ? HKD CMS (0867.HK) Follow Compare 7.960 -0.110 (-1.36%) As of 9:36 AM GMT+8. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations China Medical System：First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area SHENZHEN, CHINA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. GlobeNewswire ? 18 days ago CHSYF 3 Dividend Stocks On SEHK Yielding Up To 6.1% As Hong Kong's Hang Seng Index experiences a significant rally, buoyed by China's recent stimulus measures, investors are increasingly looking at dividend stocks as a reliable source of income amidst the market's volatility. In this context, selecting stocks with strong fundamentals and consistent dividend payouts can be particularly appealing for those seeking stability and potential returns in an evolving economic landscape. Simply Wall St. ? last month 0883.HK 80883.HK CHSYF China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, followi GlobeNewswire ? last month CHSYF Top SEHK Dividend Stocks Including Lion Rock Group Amid a backdrop of global economic uncertainty and fluctuating market conditions, the Hong Kong market has shown resilience, with investors keenly eyeing stable dividend-paying stocks. In this article, we will explore three top dividend stocks listed on the SEHK, including Lion Rock Group, highlighting their potential to provide consistent returns in these volatile times. Simply Wall St. ? last month CHSYF 1127.HK TGRNF 3 SEHK Stocks That May Be Undervalued In September 2024 As global markets experience a mixed performance, the Hong Kong market has shown resilience with the Hang Seng Index gaining 2.14% recently. Amidst this environment, identifying undervalued stocks can be an effective strategy for investors looking to capitalize on potential growth opportunities. Simply Wall St. ? 2 months ago 1858.HK 3316.HK CHSYF 3 SEHK Dividend Stocks Yielding Over 6% For Your Portfolio The Hong Kong market has shown resilience amid global economic uncertainties, with the Hang Seng Index recently posting a 1.99% gain. As investors navigate these fluctuating conditions, dividend stocks yielding over 6% can offer a reliable income stream and potential portfolio stability. Simply Wall St. ? 2 months ago 3988.HK CHBJF CHCJY SEHK Value Stocks Estimated To Be Undervalued In August 2024 As global markets continue to navigate economic uncertainties, the Hong Kong stock market has shown resilience with the Hang Seng Index gaining 1.99% recently. In this environment, identifying undervalued stocks can offer potential opportunities for investors looking to capitalize on market inefficiencies. In this article, we will explore three stocks listed on the SEHK that are estimated to be undervalued as of August 2024. These selections are based on their strong fundamentals and... Simply Wall St. ? 2 months ago ESRCF CHSYF 2268.HK China Medical System （00867） Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%.SHENZHEN, CHINA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover GlobeNewswire ? 2 months ago CHSYF Top Dividend Stocks On SEHK To Consider In August 2024 As global markets react to economic data and shifts in investor sentiment, the Hong Kong market has shown resilience amid broader uncertainties. With the Hang Seng Index experiencing modest declines, dividend stocks on the SEHK remain a compelling option for investors seeking stable returns in volatile times. In this environment, selecting dividend stocks with strong fundamentals and consistent payout histories can provide a reliable income stream and mitigate some of the risks associated... Simply Wall St. ? 2 months ago SHTDF SHTDY CHSYF China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The Product is a small-volume methotrexate injection with various strengths for the treatment of active rheumat GlobeNewswire ? 2 months ago CHSYF 3 High Yield Dividend Stocks On SEHK With Up To 6.2% Yield Amidst a backdrop of fluctuating global markets, Hong Kong's stock exchange has shown resilience, with particular interest growing around high-yield dividend stocks. In the current economic environment, these stocks could appeal to investors looking for steady income streams combined with potential market stability. Simply Wall St. ? 3 months ago GZPHF CHSYF TGRNF China Medical System （867.HK） Reincluded in S&P Global Sustainability Yearbook （China Edition） and Maintained MSCI ESG “AA” Rating SHENZHEN, CHINA, July 16, 2024 (GLOBE NEWSWIRE) -- In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its "AA" rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating GlobeNewswire ? 3 months ago CHSYF China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Produc GlobeNewswire ? 4 months ago CHSYF China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue?) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the GlobeNewswire ? 4 months ago CHSYF Exploring China Hongqiao Group And Two More Leading Dividend Stocks Amidst a backdrop of fluctuating global markets, with the Hang Seng Index recently experiencing significant declines, investors are increasingly attentive to stable income streams. Dividend stocks, such as those from China Hongqiao Group and other leading entities in Hong Kong, offer potential resilience and steady returns in these uncertain times. Simply Wall St. ? 5 months ago CHSYF FIRRF FIRRY China Medical System: New Drug Application of Desidustat Tablets Accepted in China SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) -- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. China Phase III trial of the Product has demonstrated positive results. The primary endpoint has indicated that GlobeNewswire ? 6 months ago CHSYF CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a GlobeNewswire ? 7 months ago CHSYF China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%. Profit for the year was RMB2,384 million, and normalized profit for the year that excluding provisions of impairment losses GlobeNewswire ? 7 months ago CHSYF China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro? SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro? (the “Product”). Winhealth Investment and VFMCRP en GlobeNewswire ? 8 months ago CHSYF CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA SHENZHEN, CHINA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- On 29 December, 2023, PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by China Medical System Holdings Limited (“CMS”), through its wholly-owned subsidiary CMS MEDICAL VENTURE PTE. LTD., and its non-wholly owned subsidiary Rxilient Health Pte. Ltd., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and Healthy Goal Limited (“Legend Fund”), has entered into a lease agreement for the building and proper GlobeNewswire ? 9 months ago CHSYF Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX Return 0867.HK HANG SENG INDEX YTD -40.48% +21.76% 1-Year -37.12% +17.50% 3-Year -27.86% -16.54%
